Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.
Vincenzi, B., Badalamenti, G., Napolitano, A., Spalato Ceruso, M., Pantano, F., Grignani, G., et al. (2017). Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 118, 1-6 [10.1016/j.critrevonc.2017.06.006].
Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas
Badalamenti, G.;Russo, A.;Santini, D.;
2017-01-01
Abstract
Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Vincenzi et al. olaratumab .pdf
Solo gestori archvio
Dimensione
855.98 kB
Formato
Adobe PDF
|
855.98 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
